Gilead buys remaining rights to cancer immunotherapy drug from partner Jounce - Silicon Valley Business Journal

Gilead Sciences Inc. will pay $67 million for the remaining rights to a cancer immunotherapy drug from partner Jounce Therapeutics Inc., a move to strengthen the Foster City-based drug maker's pipeline of potential cancer drugs.

GS-1811 is designed to selectively deplete immune system-suppressing T regulatory cells that infiltrate the area in and around tumors, giving the body's immune system a better chance at fighting off the cancer. "GS-1811, with its potential new pathway of activating the immune system, gives us the opportunity to potentially change the standard of care with a treatment works from inside cancerous cells to shrink solid tumors," said Dr.Richard Murray

مصر أحدث الأخبار, مصر عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Gilead buys remaining rights to cancer immunotherapy drug from partner Jounce - San Francisco Business Times$GILD buys out rights to early-stage $JNCE cancer drug as part of ongoing efforts to beef up its cancer drug pipeline.
مصدر: SFBusinessTimes - 🏆 78. / 68 اقرأ أكثر »

S.F. grocery delivery giant Instacart trims valuation - Silicon Valley Business JournalInstacart cut its meaty valuation back in March. Here's how much it's just trimmed it again. bayarea technews
مصدر: svbizjournal - 🏆 334. / 59 اقرأ أكثر »